<DOC>
	<DOCNO>NCT00144170</DOCNO>
	<brief_summary>The objective study demonstrate safety efficacy tipranavir/ritonavir versus active control arm highly treatment experience Human immunodeficiency virus-1 infected patient . Patients must viral load &gt; =1000 cells/mL , genotype indicate least one resistance confer protease inhibitor-mutation determine predefined panel mutation . Any CD4+ count acceptable .</brief_summary>
	<brief_title>Tipranavir/Ritonavir vs. Genotypically Defined Protease Inhibitor/Ritonavir HIV Patients ( RESIST-2 )</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<mesh_term>Tipranavir</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<criteria>1 . Signed informed consent prior trial participation . 2 . Human immunodeficiency virus1 infect male female &gt; =18 year age . 3 . Screening genotypic resistance report indicate follow : least one primary protease mutation follow site 30N , 46I/L , 48V , 50V , 82A/F/L/T , 84V 90M , two protease mutation codon 33 , 82 , 84 , 90 . 4 . At least 3 consecutive month experience take antiretrovirals class Nucleoside reverse transcriptase inhibitor ( ) , Nonnucleoside reverse transcriptase inhibitor ( ) , Protease inhibitor ( ) point treatment history , least 2 Protease inhibitorbased regimen ( minimum 3 month exposure ) , one must part current regimen , current Protease inhibitorbased antiretroviral medication regimen least 3 month prior randomisation . 5 . Human immunodeficiency virus1 viral load &gt; =1000 copies/mL screening . 6 . Acceptable screen laboratory value indicate adequate baseline organ function . Laboratory value consider acceptable follow apply : Total cholesterol &lt; =400 mg/dl 10,36 mm/L . Total triglyceride &lt; =750 mg/dl 8,5 mm/L . Alanine aminotransferase &lt; =3x upper limit normal aspartate aminotransferase &lt; =2.5x upper limit normal . Any Grade gammaglutamyl transpeptidase acceptable . Any Grade creatinine kinase acceptable long concurrent myopathy . All laboratory test value &lt; = Grade 1 ( Division Acquired immune deficiency syndrome , National Institute Health grade scale ) . 7 . Acceptable medical history , assess investigator , chest Xray electrocardiogram within 1 year study participation . 8 . Willingness abstain ingest substance study may alter plasma study drug level interaction cytochrome P450 system . 9 . A prior Acquired immune deficiency syndromedefining event acceptable long resolve patient stable treatment least 2 month ( Acquired immune deficiency syndrome relate complex acceptable ) . 1 . Antiretroviral medication na√Øve . 2 . Patients recent drug holiday , define antiretroviral medication least 7 consecutive day within last 3 month . 3 . Alanine aminotransferase &gt; 3x upper limit normal aspartate aminotransferase &gt; 2.5x upper limit normal either screening visit . 4 . Female patient childbearing potential : positive serum pregnancy test screening study , breast feeding planning become pregnant , willing use barrier method contraception , require ethinyl estradiol administration 5 . Prior tipranavir use . 6 . Use investigational medication within 30 day study entry trial . ( T20 [ enfuvirtide ] Tenofovir ( Viread ) , investigational time write protocol , allow . ) 7 . Use immunomodulatory drug within 30 day study entry trial ( e.g . interferon , cyclosporin , hydroxyurea , interleukin 2 ) . 8 . Inability adhere requirement protocol , include active substance abuse assess investigator . 9 . In opinion investigator , likely survival le 12 month underlying disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>